Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
225 stopped studies mapped to Neuroendocrine Carcinoma and descendants · 90% state a reason
Over the 225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating… | Phase 1 / Phase 2 | terminated | Oct 8, 2010 | National Cancer Institute (NCI) | Other - Protocol moved to Administratively Complete | Other (stated, no rule matched) |
| NCT03879798 | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Mar 19, 2019 | Memorial Sloan Kettering Cancer Center | Due to DLTs | Other (stated, no rule matched) |
| NCT06427369 | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer | Phase 1 | withdrawn | May 23, 2024 | Roswell Park Cancer Institute | prioritization | Other (stated, no rule matched) |
| NCT05191797 | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive… | Phase 1 / Phase 2 | terminated | Jan 14, 2022 | University of Washington | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT01904253 | A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung… | Phase 2 | terminated | Jul 22, 2013 | Taiho Oncology, Inc. | The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an… | Safety / toxicity |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | — | terminated | Dec 12, 2017 | Washington University School of Medicine | Subject recruitment was limited severely by the 2020-2023 COVID-19 pandemic, which led this study… | COVID-19 / pandemic |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy… | Phase 2 | terminated | Jan 27, 2011 | Merck Sharp & Dohme LLC | Persistent low enrollment made study continuation no longer feasible | Enrollment / accrual |
| NCT00791154 | QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer(SCLC) | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | NantCell, Inc. | Subjects discontinued study | Other (stated, no rule matched) |
| NCT03853317 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma… | Phase 2 | terminated | Feb 25, 2019 | ImmunityBio, Inc. | Not meeting recruitment goal | Enrollment / accrual |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors… | Phase 1 / Phase 2 | terminated | Nov 13, 2019 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT05572476 | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage…(LURBIMUNE) | Phase 2 | withdrawn | Oct 7, 2022 | Institut Bergonié | Recruitment difficulties, decline in the incidence of the studied pathology, active competitive… | Enrollment / accrual |
| NCT02465957 | QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) | Phase 2 | terminated | Jun 9, 2015 | ImmunityBio, Inc. | not stated | Not stated |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in… | Phase 1 / Phase 2 | terminated | Jul 12, 2013 | Kyowa Kirin Korea Co., Ltd. | lack of efficacy | Efficacy / futility |
| NCT04610658 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | Phase 1 | terminated | Oct 30, 2020 | H. Lee Moffitt Cancer Center and Research Institute | DLTs | Other (stated, no rule matched) |
| NCT03699956 | RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or…(REPLATINUM) | Phase 3 | terminated | Oct 9, 2018 | EpicentRx, Inc. | RRx-001 will be studied under a new global, phase 3 clinical trial | Other (stated, no rule matched) |
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer… | Phase 2 | terminated | Oct 30, 2020 | Jeffrey Clarke | Lack of Enrollment | Enrollment / accrual |
| NCT04352413 | A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based… | Phase 2 | terminated | Apr 20, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 25, 2023 | Hansoh BioMedical R&D Company | Research and development strategy adjustment. | Sponsor / business decision |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated…(AcceleRET-MTC) | Phase 3 | withdrawn | Feb 18, 2021 | Hoffmann-La Roche | Due to several logistical challenges during start-up which could not be overcome study was… | Other (stated, no rule matched) |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT03499678 | Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA | — | terminated | Apr 17, 2018 | HKGepitherapeutics | Encountered technical issues with blood plasma samples received from the hospital. | Other (stated, no rule matched) |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and… | Phase 1 | terminated | Jan 7, 2016 | SCRI Development Innovations, LLC | Clinical program was discontinued by Novartis | Other (stated, no rule matched) |
| NCT03995667 | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung… | Phase 2 | terminated | Jun 24, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron… | Phase 2 | terminated | Aug 28, 2018 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT04308785 | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small… | Phase 2 | terminated | Mar 16, 2020 | Hoffmann-La Roche | The sponsor's decision was based on the negative results of SKYSCRAPER-02. | Sponsor / business decision |
| NCT05161533 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of… | Phase 2 | withdrawn | Dec 17, 2021 | University of Washington | Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled. | Enrollment / accrual |
| NCT02899728 | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small… | Phase 2 | terminated | Sep 14, 2016 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and… | Phase 1 / Phase 2 | terminated | Dec 8, 2017 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT02608411 | TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)(TIMES) | Phase 2 | terminated | Nov 18, 2015 | Istituto Oncologico Veneto IRCCS | Safety results (applied in METIV-HCC trial) have led early termination | Safety / toxicity |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03963414 | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | Phase 1 | terminated | May 24, 2019 | University of Nebraska | low accrual | Enrollment / accrual |
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Phase 2 | terminated | Aug 30, 2021 | Kartos Therapeutics, Inc. | Unanticipated and extremely high screen failure rate. There was no evidence of safety concerns in… | Safety / toxicity |
| NCT04750239 | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell… | Phase 1 / Phase 2 | terminated | Feb 11, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell… | Phase 2 | withdrawn | Jun 9, 2022 | Ellipses Pharma | Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies… | Efficacy / futility |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT02036476 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jan 15, 2014 | Dana-Farber Cancer Institute | Lack of accrual. | Enrollment / accrual |
| NCT03488472 | Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain(RAD 1704) | N/A | terminated | Apr 5, 2018 | Drexell Hunter Boggs | This feasibility study only accrued one patient since site activation. We believe that the primary… | Enrollment / accrual |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or… | Phase 1 / Phase 2 | terminated | Oct 19, 2020 | Xencor, Inc. | The study has been terminated early by the sponsor due to business decision. | Sponsor / business decision |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With… | Phase 2 | terminated | Jan 23, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor closed study | Other (stated, no rule matched) |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Phase 2 | terminated | Nov 15, 2016 | Alliance Foundation Trials, LLC. | Lack of enrollment | Enrollment / accrual |
| NCT04488263 | Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | — | terminated | Jul 27, 2020 | National Cancer Institute (NCI) | To avoid the duplication of effort and resources associated with the PI's branch change. | Other (stated, no rule matched) |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung… | Phase 2 | terminated | Dec 24, 2010 | Ludwig Institute for Cancer Research | Lack of efficacy in Cohort 2; slow enrollment in Cohort 1 | Efficacy / futility |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects… | Phase 1 | terminated | Jul 17, 2019 | Aileron Therapeutics, Inc. | With a favorable safety profile the difference between treatment groups for the primary composite… | Safety / toxicity |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing…(NAC-PNP) | N/A | terminated | Mar 18, 2008 | Rijnstate Hospital | Unable to recruit enough patients | Enrollment / accrual |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 19, 2024source: clinicaltrials